InvestorsHub Logo
Followers 827
Posts 119469
Boards Moderated 15
Alias Born 09/05/2002

Re: nonsequetor post# 635

Tuesday, 04/25/2017 2:13:42 PM

Tuesday, April 25, 2017 2:13:42 PM

Post# of 1050
I don't think a 6-week HCV regimen will become the standard of care, even for (relatively easy to treat) non-cirrhotic genotype-1 patients.

If it were up to me, I would kill JNJ's 3-DAA HCV regimen unless the phase-2b in progress (with ~150 patients per arm) shows an SVR rate of at least 99% in the 6-week arm.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent JNJ News